ClinicalTrials.gg
Not yet recruitingNCT07710144Updated Jul 17, 2026

Innovative Mouthwash in School-Aged Children With Fixed Orthodontic Appliances

An interventional study of Test mouthwash and Chlorhexidine-containing mouthwash in Plaque-Induced Gingivitis, Dental Plaque Accumulation and Halitosis, sponsored by Plovdiv Medical University. Not yet recruiting at 1 site in Bulgaria. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Plovdiv Medical University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

Fixed metal orthodontic appliances create additional plaque-retentive areas around brackets, archwires and ligatures, making mechanical plaque control more difficult in children and adolescents. Increased plaque accumulation may contribute to gingival inflammation, bleeding, halitosis and early enamel changes. Therefore, adjunctive preventive agents, including mouthwashes, may be clinically useful as part of a comprehensive oral hygiene program during fixed orthodontic treatment.

The aim of the study is to evaluate the clinical effectiveness and tolerability of a test mouthwash in children and adolescents with fixed orthodontic appliances by monitoring plaque accumulation, gingival inflammation, gingival bleeding and halitosis.

02

Conditions studied

  • Plaque-Induced Gingivitis
  • Dental Plaque Accumulation
  • Halitosis

Browse trials for

03

In context

Halitosis

93 studies on the registry are indexed under Halitosis; 17 are open to participants now.

This study's planned enrollment of 90 is above the median of 45 across 79 interventional studies indexed under Halitosis.

Browse Halitosis studies →

Lead sponsor

Plovdiv Medical University is the lead sponsor of 16 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged 12 to 17 years.
  2. Presence of fixed metal orthodontic appliances placed at least 6 months before enrollment.
  3. Generalized plaque-induced gingivitis.
  4. Full Mouth Bleeding Score greater than 30%.
  5. Gingival Index greater than 0.95 according to Loe and Silness.
  6. Written obtained from a parent or legal guardian.
  7. Participant willingness to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Refusal to participate or withdrawal of .
  2. Non-compliance with the intervention regimen or inability to attend follow-up visits.
  3. Development of an adverse reaction or condition requiring discontinuation.
  4. Antibiotic or antimicrobial therapy during follow-up if it may affect the study outcomes.
  5. Presence of concomitant systemic diseases.
  6. Current systemic medication intake that could influence oral health or inflammatory status.
  7. Use of systemic or local antimicrobial agents during the previous 3 months, including mouthwashes, gels, chewing gums or other local oral agents.
  8. Known allergy or to any component of the tested mouthwash formulations.
  9. Use of removable orthodontic appliances only. Inability or unwillingness to follow the study instructions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Test Mouthwash

    Participants rinsed with 15 ml of the prototype chlorhexidine-free pediatric mouthwash for 30-60 seconds twice daily for 21 days as an adjunct to standard oral hygiene.

    Other: Test mouthwash

  • Active comparator
    Chlorhexidine Mouthwash

    Participants rinsed with a 15 ml chlorhexidine-containing mouthwash for 30-60 s twice daily for 21 days as an adjunct to standard oral hygiene.

    Other: Chlorhexidine-containing mouthwash

  • Placebo comparator
    Placebo Mouthwash Group

    Participants rinsed with 15 ml of the placebo mouthwash for 30-60 seconds twice daily for 21 days as an adjunct to standard oral hygiene.

    Other: Placebo mouthwash

Interventions

  • OtherTest mouthwash

    Participants rinsed with a 15 ml prototype chlorhexidine-free pediatric mouthwash for 30-60 s twice daily for 21 days as an adjunct to standard oral hygiene.

    Also known as: Sample 1

  • OtherChlorhexidine-containing mouthwash

    Participants rinsed with a 15 ml chlorhexidine-containing mouthwash for 30-60 s twice daily for 21 days as an adjunct to standard oral hygiene.

    Also known as: Eludril classic®, Positive control

  • OtherPlacebo mouthwash

    Participants rinsed with a 15 ml placebo mouthwash for 30-60 s twice daily for 21 days as an adjunct to standard oral hygiene.

06

What researchers measure

Primary outcomes

  1. Orthodontic Plaque Index (OPI)

    The Orthodontic Plaque Index focuses on the areas around the bracket, which represents an additional plaque-retentive factor. The dentition is divided into sextants and plaque accumulation is scored from 0 to 4. The mesial, distal, incisal and cervical areas around each bracket are evaluated. The highest score among all sextants defines the oral hygiene level and identifies the need for preventive measures. Registry field data Code 0 No plaque accumulation is detected. Code 1 Plaque accumulation is detected on one tooth surface around the bracket base. Code 2 Plaque accumulation is detected on two tooth surfaces around the bracket base. Code 3 Plaque accumulation is detected on three tooth surfaces around the bracket base; increased risk of caries and gingivitis is assumed. Code 4 Plaque accumulation is detected on all tooth surfaces around the bracket base and/or gingival inflammation is present.

    Time frame: Baseline, day 7, day 21, and 3 months

  2. Gingival Index (Loe & Silness)

    The index evaluates color, contour and bleeding of the gingival tissues. A World Health Organization (WHO) 621 periodontal probe is used to examine the gingival sulcus, and bleeding is recorded within 10 seconds. Code 0 Normal gingiva. Code 1 Mild inflammation: slight color change and slight edema, without bleeding on probing. Code 2 Moderate inflammation: redness, edema and glazing, with bleeding on probing. Code 3 Severe inflammation: marked redness and edema, ulceration and tendency to spontaneous bleeding.

    Time frame: Baseline, day 7, day 21, and 3 months

  3. Full Mouth Bleeding Score (FMBS)

    FMBS assesses provoked bleeding from the gingival sulcus using a WHO 621 periodontal probe. Bleeding is recorded within 10 seconds and marked as present (+) or absent (-). The index is calculated as the percentage of gingival sites with provoked bleeding from all examined sites for each child.

    Time frame: Baseline, day 7, day 21, and 3 months

  4. Full Mouth Plaque Score (FMPS)

    Dental plaque accumulation was assessed using the Full Mouth Plaque Score. The presence of visible plaque was recorded on tooth surfaces, and the result was expressed as the percentage of plaque-positive sites. Lower percentages indicate improved plaque control.

    Time frame: Baseline, day 7, day 21, and 3 months

Secondary outcomes

  1. Halitosis Assessment

    Halitosis was assessed by gas chromatography using OralChroma™. Volatile sulfur compounds were measured, including hydrogen sulfide, methyl mercaptan and dimethyl sulfide.

    Time frame: Baseline, day 7, day 21, and 3 months

07

Study locations

1 site
  • Department of Paediatric dentistry, Faculty of Dental Medicine, Medical University of Plovdiv
    Plovdiv, 4000, Bulgaria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 35 non-industry interventional studies with no phase under Halitosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 3 months is below that.

Counting every sponsor, half of 43 studies reached it within 10 months; a quarter within 3 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 17, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2028
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07710144
Lead sponsor
Plovdiv Medical University
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Tanya Zalamova
Contact
tanya.zalamova@mu-plovdiv.bg
00359878752567
Ani Belcheva, PhD
Contact
abeltcheva@gmail.com
Tanya Zalamova
principal investigator · Plovdiv Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion